Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Abstract
There have been numerous important recent advances in our understanding of the causes of Parkinson's disease (PD), the treatments available and how these are best applied for the long-term management of patients. Novel genes causing familial PD have been discovered and mechanisms leading to cell dysfunction and death identified. The PD prodrome is now a subject of great interest and clinical markers are being defined that may in future, together with biochemical markers, support an early, pre-motor diagnosis of PD. This will become important as new therapies are developed to modify disease progression. In the interim, the optimization of existing therapies remains an important priority. The value of existing and novel continuous drug delivery systems in PD is seen as providing simplified regimens, maintenance of motor control, reduction in motor complications and improved patient adherence to drug use.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dopamine replacement therapy alleviates some motor features of Parkinson's disease but has less beneficial effects on cognitive function.
“DA replacement therapy alleviates some motor features of PD, but with less beneficial effects observed on cognitive function 4.”
From Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease (2013) · cites this paper as [4]
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536 · see citing works
Self-citationα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · see citing works
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · see citing works
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A. A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M. J., Lincoln, S., Kachergus, J. M., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,024 · see citing works
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · see citing works
Self-citationNon-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, К. R., & Schapira, A. H. V. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,739 · see citing works
Self-citationRascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539 · see citing works
Self-citationHealy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Dürr, A., Bressman, S., Brice, A., Aasly, J. O., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,523 · see citing works
Self-citationChaudhuri, K. R., Martinez‐Martin, P., Schapira, A. H. V., Stocchi, F., Sethi, K., Odin, P., Brown, R. G., Koller, W., Barone, P., MacPhee, G., et al. (2006) · Movement Disorders · doi:10.1002/mds.20844 · Cited by 1,100 · cited 2× · see citing works
“Large cohorts of PD patients have been screened for NMS by means of validated tools including the nonmotor questionnaire (NMS Quest), the non-motor scale (NMS Scale) [28], and the new Unified Parkinson”
MethodSelf-citationIranzo, Á., Molinuevo, J. L., Santamaría, J., Serradell, M., Martı́, M. J., Valldeoriola, F., & Tolosa, E. S. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70476-8 · Cited by 950 · see citing works
Self-citationMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · see citing works
Self-citationComparison of kindreds with parkinsonism and α‐synuclein genomic multiplications
Farrer, M. J., Kachergus, J. M., Forno, L. S., Lincoln, S., Wang, D., Hulihan, M., Maraganore, D. M., Gwinn, K. A., Wszołek, Z. K., Dickson, D. W., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10846 · Cited by 699 · see citing works
Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.013 · Cited by 682 · see citing works
Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study
Aarsland, D., Brønnick, K., Larsen, J. P., Tysnes, O. B., & Alves, G. (2009) · Neurology · doi:10.1212/01.wnl.0000338632.00552.cb · Cited by 625 · see citing works
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 559 · see citing works
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease
Pan, T., Kondo, S., Le, W., & Jankovic, J. J. (2008) · Brain · doi:10.1093/brain/awm318 · Cited by 546 · see citing works
Factors impacting on quality of life in Parkinson's disease: Results from an international survey
The Global Parkinson's Disease Survey (GPDS) Steering Committee (2002) · Movement Disorders · doi:10.1002/mds.10010 · Cited by 521 · see citing works
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Mosley, R. L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 423 · see citing works
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M. A., Dobkin, R. D., Marín, H., Mark, M. H., Gara, M. A., Buyske, S. G., Bienfait, K., & Dicke, A. (2008) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 413 · see citing works
Poewe, W. H., Rascol, O., Quinn, N. P., TOLOSA, E. S., Oertel, W. H., Martignoni, E., Rupp, M., & Boroojerdi, B. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70108-4 · Cited by 399 · see citing works
Self-citationPotential early markers of Parkinson disease in idiopathic REM sleep behavior disorder
Postuma, R. B., Lang, A. E., Massicotte-Marquez, J., & Montplaisir, J. Y. (2006) · Neurology · doi:10.1212/01.wnl.0000203648.80727.5b · Cited by 392 · see citing works
A critical evaluation of the Braak staging scheme for Parkinson's disease
Burke, R. E., Dauer, W. T., & Vonsattel, J. P. (2008) · Annals of Neurology · doi:10.1002/ana.21541 · Cited by 377 · see citing works
Goetz, C. G., Poewe, W. H., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376 · see citing works
Self-citationSUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS
Stibe, C., Kempster, P. A., Lees, A. J., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91193-2 · Cited by 323 · see citing works
ANAPHYLACTIC REACTION TO BCG VACCINATION
Harper, J. R. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91438-6 · Cited by 319 · see citing works
α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia
Parkkinen, L., Kauppinen, T., Pirttilä, T., Autere, J. M., & Alafuzoff, I. I. (2004) · Annals of Neurology · doi:10.1002/ana.20321 · Cited by 315 · see citing works
Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease
Voon, V., Thomsen, T. R., Miyasaki, J. M., de Souza, M., Shafro, A., Fox, S. H., Duff-Canning, S. J., Lang, A. E., & Zurowski, M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.212 · Cited by 308 · see citing works
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bézard, E., Brotchie, J. M., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, É. C., Jenner, P. G., Novère, N. G. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 303 · see citing works
Self-citationWilliams, D. R., & Lees, A. J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70146-0 · Cited by 302 · see citing works
Horstink, M. W. I. M., TOLOSA, E. S., Bonuccelli, U., Deuschl, G., Friedman, A., Kaňovský, P., Larsen, J. O., Lees, A. J., Oertel, W. H., Poewe, W. H., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 296 · see citing works
Self-citationNonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study
O'Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira‐Moriyama, L., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.21813 · Cited by 290 · see citing works
Neuroprotection in Parkinson Disease
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 290 · see citing works
Self-citationON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE
Hardie, R. J., Lees, A. J., & Stern, G. M. (1984) · Brain · doi:10.1093/brain/107.2.487 · Cited by 278 · see citing works
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J. A., Schrag, A. E., Ben‐Shlomo, Y., Evans, A. L., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 273 · see citing works
Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008) · Movement Disorders · doi:10.1002/mds.21966 · Cited by 270 · see citing works
Diagnosis and the premotor phase of Parkinson disease
TOLOSA, E. S., Gaig, C., Santamaría, J., & Compta, Y. (2009) · Neurology · doi:10.1212/wnl.0b013e318198db11 · Cited by 257 · see citing works
Self-citationNeurobiology and treatment of Parkinson's disease
Schapira, A. H. V. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.005 · Cited by 252 · see citing works
Self-citationRandomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
Watts, R. L., Jankovic, J. J., Waters, C., Rajput, A. H., Boroojerdi, B., & Rao, J. M. (2007) · Neurology · doi:10.1212/01.wnl.0000252355.79284.22 · Cited by 249 · see citing works
Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease
Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, F., Bracco, F., Zappia, M., Musch, B., & and the Depression/Parkinson Italian Study Group (2006) · Journal of Neurology · doi:10.1007/s00415-006-0067-5 · Cited by 247 · see citing works
Self-citationControl of on/off phenomenon by continuous intravenous infusion of levodopa
Quinn, N. P., Parkes, J. D., & Marsden, C. D. (1984) · Neurology · doi:10.1212/wnl.34.9.1131 · Cited by 232 · see citing works
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231 · see citing works
Self-citationThe natural history of Parkinson’s disease
Poewe, W. H. (2006) · Journal of Neurology · doi:10.1007/s00415-006-7002-7 · Cited by 230 · see citing works
Self-citationIntermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease
Stocchi, F., Vacca, L., Ruggieri, S. A., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229 · see citing works
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S., & Pearce, R. K. B. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00923.x · Cited by 224 · see citing works
Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome
Antonini, A., Isaias, I. U., Canesi, M., Zibetti, M., Mancini, F., Manfredi, L., Fante, M. D., Lopiano, L., & Pezzoli, G. (2007) · Movement Disorders · doi:10.1002/mds.21500 · Cited by 218 · see citing works
Pearce, R. K. B., Banerji, T., Jenner, P. G., & MARSDEN, C. D. (1998) · Movement Disorders · doi:10.1002/mds.870130207 · Cited by 218 · see citing works
Self-citationSuboptimal medication adherence in Parkinson's disease
Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 206 · see citing works
Gegg, M. E., Cooper, J. M., Schapira, A. H. V., & Taanman, J.-W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004756 · Cited by 198 · see citing works
Self-citationIncidental Lewy Body Disease and Preclinical Parkinson Disease
DelleDonne, A., Klos, K. J., Fujishiro, H., Ahmed, Z., Parisi, J. E., Josephs, K. A., Frigerio, R., Burnett, M. S., Wszołek, Z. K., Uitti, R. J., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1074 · Cited by 197 · see citing works
LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study
Hulihan, M., Ishihara-Paul, L., Kachergus, J. M., Warren, L. L., Amouri, R., Elango, R., Prinjha, R. K., Upmanyu, R., Kefi, M., Zouari, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70116-9 · Cited by 191 · see citing works
Why have we failed to achieve neuroprotection in Parkinson's disease?
Olanow, C. W., Kieburtz, K. D., & Schapira, A. H. V. (2009) · Annals of Neurology · doi:10.1002/ana.21461 · Cited by 184 · see citing works
Self-citationGrosset, D. G., Taurah, L., Burn, D. J., MacMahon, D. G., Forbes, A. B., Turner, K., Bowron, A., Walker, R. W., Findley, L. J. J., Föster, O., et al. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.098327 · Cited by 181 · see citing works
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177 · see citing works
Self-citationScience, medicine, and the future: Parkinson's disease.
Schapira, A. (1999) · British medical journal · doi:10.1136/bmj.318.7179.311 · Cited by 174 · see citing works
Self-citationOxidative Stress and Parkinson's Diseasea
Owen, A., Schapira, A. H. V., Jenner, P. G., & MARSDEN, C. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb39064.x · Cited by 154 · see citing works
Self-citationKurth, M., Tetrud, J. W., Tanner, C. M., et al. (1993) · Neurology · doi:10.1212/wnl.43.9.1698 · Cited by 146 · see citing works
The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson???s Disease
Bracco, F., Battaglia, A., Chouza, C., et al. (2004) · CNS Drugs · doi:10.2165/00023210-200418110-00003 · Cited by 142 · see citing works
Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations
Kurlan, R., Rubin, A. J., Miller, C. D., Rivera‐Calimlim, L., Clarke, A., & Shoulson, I. (1986) · Annals of Neurology · doi:10.1002/ana.410200213 · Cited by 140 · see citing works
Dopamine agonists in Parkinson's disease: a look at apomorphine
Lees, A. (1993) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00226.x · Cited by 135 · see citing works
Brás, J., Singleton, A., Cookson, M., & Hardy, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06709.x · Cited by 132 · see citing works
Etiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 118 · see citing works
Self-citationEnteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease
Nyholm, D., Lewander, T., Johansson, A., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180ed449f · Cited by 117 · see citing works
Grünewald, A., Gegg, M. E., Taanman, J., King, R. H. M., Kock, N., Klein, C., & Schapira, A. H. V. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.027 · Cited by 110 · see citing works
Self-citationFunctional models of Parkinson's disease: A valuable tool in the development of novel therapies
Jenner, P. G. (2009) · Annals of Neurology · doi:10.1002/ana.21489 · Cited by 107 · see citing works
Self-citationRelationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia
Santangelo, G., Vitale, C., Trojano, L., Longo, K., Cozzolino, A., Grossi, D., & Barone, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0146-5 · Cited by 101 · see citing works
Self-citationJenner, P. G. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s47 · Cited by 94 · see citing works
Self-citationTen years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease
Syed, N. A., Murphy, J., Zimmerman, T. R., Mark, M. H., & Sage, J. I. (1998) · Movement Disorders · doi:10.1002/mds.870130222 · Cited by 94 · see citing works
Can we image premotor Parkinson disease?
MAREK, K. L., & Jennings, D. L. (2009) · Neurology · doi:10.1212/wnl.0b013e318198df97 · Cited by 92 · see citing works
The need for neuroprotective therapies in Parkinson’s disease
Poewe, W. H. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s2 · Cited by 84 · see citing works
Self-citationContinuous dopaminergic stimulation in early and advanced Parkinson’s disease
Stocchi, F., & Olanow, C. W. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s56 · Cited by 84 · see citing works
Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment
Siderowf, A. D., & Stern, M. B. (2009) · Annals of Neurology · doi:10.1002/ana.21462 · Cited by 84 · see citing works
The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism
DePaolo, J., Göker-Alpan, Ö., Samaddar, T., Lopez, G. J., & Sidransky, E. (2009) · Movement Disorders · doi:10.1002/mds.22538 · Cited by 79 · see citing works
Maratos, E. C., Jackson, M. J., Pearce, R. K. B., et al. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8055 · Cited by 76 · see citing works
Lees, A. J. (2009) · Neurology · doi:10.1212/wnl.0b013e318198daec · Cited by 71 · see citing works
Dystonia in the Woodhouse Sakati syndrome: A new family and literature review
Schneider, S. A., & Bhatia, K. P. (2008) · Movement Disorders · doi:10.1002/mds.21886 · Cited by 67 · see citing works
Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
Schapira, A. H. V. (2009) · Neurology · doi:10.1212/wnl.0b013e3181990438 · Cited by 67 · see citing works
Self-citationPreclinical diagnosis of parkinson’s disease: Are we there yet?
Siderowf, A. D., & Stern, M. B. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0021-z · Cited by 64 · see citing works
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease
Obeso, J. A., Luquín, M. R., & Lage, J. M. M. (1986) · Annals of Neurology · doi:10.1002/ana.410190107 · Cited by 54 · see citing works
Genomic and proteomic biomarkers for Parkinson disease
Gasser, T. (2009) · Neurology · doi:10.1212/wnl.0b013e318198e054 · Cited by 54 · see citing works
The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
Nyholm, D. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.005 · Cited by 54 · see citing works
Smith, L. A., Jackson, M. J., Johnston, L. C., Kuoppamäki, M., Rose, S., Al‐Barghouthy, G., Signore, S. D., & Jenner, P. G. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000220818.71231.df · Cited by 53 · see citing works
Self-citationJackson, M. J., Smith, L. A., Al‐Barghouthy, G., Rose, S., & Jenner, P. G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.005 · Cited by 46 · see citing works
Self-citationNissinen, H., Kuoppamäki, M., Leinonen, M., & Schapira, A. H. V. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02726.x · Cited by 34 · see citing works
Self-citationUniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant
Tan, E., & Schapira, A. H. V. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02053.x · Cited by 27 · see citing works
Self-citationZubair, M., Jackson, M. J., Tayarani‐Binazir, K. A., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.002 · Cited by 24 · see citing works
Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset
Nomoto, M., Stahl, S. M., Jenner, P., et al. (1987) · Movement Disorders · doi:10.1002/mds.870020105 · Cited by 23 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease
Petzinger, G. M., Fisher, B. E., McEwen, S., Beeler, J. A., Walsh, J. P., & Jakowec, M. W. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70123-6 · Cited by 798 · see citing works
Parsons, C. G. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.027 · Cited by 22 · see citing works
- Authors
- Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E.
- Affiliations
- UCL Queen Square Institute of Neurology (GB)
- Inserm (FR)
- University of Naples Federico II (IT)
- King's College London (GB)
- Christian-Albrechts-Universität zu Kiel (DE)
- Innsbruck Medical University (AT)
- University Hospital Carl Gustav Carus (DE)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Schapira, A. H.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2009-09-14
- Volume
- 16
- Issue
- 10
- Pages
- 1090-1099
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2090946270
- Cited by
- 69
- References
- 87
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 8 · 2013: 6 · 2012: 5
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, familial Parkinson's disease, prodromal symptoms, early diagnosis, clinical biomarkers, biochemical markers, long-term management, continuous drug delivery, motor complications, medication adherence
- MeSH terms
- Autophagy, Cognition Disorders, Depression, Humans, Neurons, Parkinson Disease, Drug Delivery Systems, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
